血清CA_(125)检测对绝经后子宫内膜癌的临床应用价值

Clinical value of serum CA_(125) determination for postmenopausal uterine endometrial carcinoma

目的 探讨血清CA12 5检测对绝经后子宫内膜癌术前判定分期、深肌层浸润、淋巴结转移和术后监测复发的价值及其与组织学类型和病理学分级的关系。 方法 用酶联免疫分析方法检测 6 7例绝经后子宫内膜癌患者术前血清CA12 5水平。 结果 Ⅲ、Ⅳ期子宫内膜癌患者的CA12 5水平明显高于Ⅰ、Ⅱ期 (P <0 0 1) ,血清CA12 5水平术前诊断晚期 (Ⅲ、Ⅳ期 )子宫内膜癌的敏感性和特异性分别为 87 5 %和 96 1% ;有深肌层浸润患者的CA12 5水平 (84 9U/ml)明显高于浅肌层浸润和无肌层浸润者 (分别为 15 6U/ml和 7 3U/ml,P <0 0 1) ,血清CA12 5水平术前诊断深肌层浸润的敏感性和特异性分别为 72 2 %和 93 9% ;有淋巴结转移患者的CA12 5水平明显高于无淋巴结转移组 (分别为 86 1U/ml和 14 8U/ml,P <0 0 1) ,血清CA12 5水平术前诊断盆腔淋巴结转移的敏感性和特异性分别为92 9%和 94 3% ;所有复发患者的血清CA12 5均为阳性 ;乳头状浆液性腺癌患者的血清CA12 5水平 (6 9 4U/ml)明显高于腺癌 (2 8 6U/ml) ;各病理学分级间血清CA12 5水平差异无显著性。 结论 血清CA12 5检测对绝经后子宫内膜癌患者术前判定临床分期、深肌层浸润。

Objective To assess preoperative value of serum CA 125 determination for uterine endometrial carcinoma including myometrial invasion, lymph node metastasis, surveillance and recurrence of the carcinoma. To explore the relationship between serum CA 125 levels and pathological grades of endometrial carcinoma. Methods Serum CA 125 levels were determined by ELISA test in 67 cases of postmenopausal endometrial carcinoma. Results There were significant differences in CA 125 levels between patients with clinical stage Ⅲ、 Ⅳ cases and clinical stage Ⅰ, Ⅱ ( P <0.01). Serum CA 125 levels of 10 cases with recurrent carcinoma were positive. Serum CA 125 levels of patients with papillary serous adenocarcinoma were significantly higher than those of adenocarcinoma. No relation was found between pathological grades and serum CA 125 levels. Conclusions Serum CA 125 levels was a useful clinical parameter for determination of postmenopausal endometrial carcinoma preoperatively.